PROM1 and colorectal cancer: Another study shows that improving the targeted delivery of the topoisomerase inhibitor SN-38 by incorporating it into PEG–PCL-based nanoparticles with anti-CD133 mAb increases the cytotoxic effects of SN-38 toward colorectal cancer cells and tumor xenografts [258].